x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Bio Report

Levine Media Group

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

science life sciences

All Episodes

08:54

A Nose for Attacking Cancer

The Bio Report ·

2025/02/05

One of the challenges in treating brain cancer and other diseases of the central nervous system is delivering therapeutics beyond the blood-brain barrier. NeOnc Technologies using a natural compound derived from essential oils in plants that not only can kill cancer cells, but can cross the blood-brain barrier. What’s more, it can transport other therapies as well. We spoke to Thomas Chen, founder and CEO of NeOnc, about brain cancer, how the blood-brain barrier complicates the delivery of therapies

en

24:52

An Unnatural Approach to Undruggable Targets

The Bio Report ·

2025/01/29

Some 70 percent of potential therapeutic targets are believed to be beyond the reach of conventional small molecule therapies or biologics. Macrocyclic peptides offer a way to get at elusive targets while providing desirable characteristics of both small molecule drugs and biologics. They offer oral bioavailability, can permeate cells, and engage complex targets with specificity. Unnatural Products is harnessing AI to create synthetic macrocyclic peptides to pursue previously undruggable targets. We

en

33:52

Expanding the Drug Developer’s Chemical Universe

The Bio Report ·

2025/01/22

Through the creation of a chemical programming language, Chemify said it has been able to expand the chemical space it can explore. Chemify is combining this unique programming language with robotics and AI to digitize chemistry. The company, though, has much grander ambitions than being a drug developer. It wants to be the infrastructure for the industry. We spoke to Lee Cronin, founder and CEO of Chemify, about the company’s platform technology for digitizing chemistry, how its chemical

en

29:20

Take 100 Megabytes a Day and Call Me in the Morning

The Bio Report ·

2025/01/15

Prescription digital therapies, the use of software to treat disease, are growing in number. Already there have been 140 prescription digital therapies that have been granted market access through national regulatory and reimbursement pathways. That represents a five-fold increase in the since 2021, according to the IQVIA Digital Health Trends 2024 report. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about the report, why digital health companies faced

en

34:25

Extracting the Benefits of Psychedelics

The Bio Report ·

2025/01/08

There has been growing interest in the potential of psychedelics to treat a variety of mental health conditions. While some focus has been put on synthesizing compounds that can target the receptors psychedelics bind to without inducing their hallucinatory effects, Filament Health is taking a notably different approach. The company, co-founded by Ben Lightburn who previously ran a firm specializing in natural extraction technologies, is focusing on developing pharmaceutical grade botanical drugs

en

37:40

A Magellan that Circumnavigates Active Binding Sites

The Bio Report ·

2025/01/01

Gain Therapeutics' platform technology Magellan leverages AI, structural biology, and physics-based models to identify novel binding sites on otherwise undruggable proteins implicated in diseases. The company’s experimental Parkinson’s disease therapy has the potential to slow or stop progression of the neurodegenerative condition by stabilizing a lysosomal enzyme implicated in the disease. We spoke to Gene Mack, CEO of Gain, about the company’s platform technology, how its experimental therapy for

en

40:28

A Very Meh-Ry Biotech Year and What’s Ahead in 2025

The Bio Report ·

2024/12/25

We continue our holiday tradition by welcoming STAT News Senior Biotech Writer Adam Feuerstein for our annual look back at the year that was in biotech and what’s ahead for the industry with the JPMorgan Healthcare conference and beyond in 2025. Feuerstein offers his view on finance and dealmaking in 2024, new drug approvals, and his annual take on the best and worst CEOs of the year. We also discuss what Trump 2.0 may look like for the industry, changes coming to the FDA and other agencies, and

en

33:43

Using Light to Biomanufacture a Steak

The Bio Report ·

2024/12/18

Prolific Machines uses light to precisely control virtually any function in any cell to transform what is possible with biomanufacturing. In combination with optogenetics and AI, the technology has the potential to impact a wide range of industries, from food production to pharmaceuticals, by enabling new capabilities, reducing costs, and improving sustainability. We spoke to Deniz Kent, co-founder and CEO of Prolific Machines, about the company’s photomolecular platform technology, the benefits it

en

34:46

Sit, Stay, and Heal: Bringing Precision Medicine to...

The Bio Report ·

2024/12/11

ImpriMed is working to deliver on the promise of precision medicine by using a patient’s live cancer cells to see how they respond to different treatment options and artificial intelligence to predict which medicines will work best. The company has had impressive results with its customers to date, but the catch is that it has initially targeted its service to the veterinary market, and its dogs and cats have benefited from it. The company is now working to bring its offering to two-legged patients

en

32:31

Targeting the Undruggable Proteome

The Bio Report ·

2024/12/04

One of the limitations of small molecule drugs and monoclonal antibodies is the difficulty they face in binding to a large number of proteins that could prove to be critical targets in combating various diseases. Aikium is harnessing the power of artificial intelligence and synthetic biology to create a new class of protein biologics called SeqRs that are designed to bind to disordered regions of proteins that have long been beyond the reach of traditional therapeutics. We spoke to Eswar Iyer,

en

36:44

Preventing a Deadly Disease by Detecting It Before It...

The Bio Report ·

2024/11/26

Esophageal cancer is a growing healthcare concern with a steady increase in the number of cases in the last four decades, a development that runs counter to what’s been seen in other major types of cancer. Some 22,000 people are diagnosed each year in the United States with the disease and it is responsible for 16,000 deaths annually. Now, though, Lishan Aklog, chairman and CEO of Lucid Diagnostics, says today esophageal cancer is preventable through early detection in the pre-cancer stage. We spoke

en

25:08

Getting Tumors to Say “Eat Me”

The Bio Report ·

2024/11/20

While existing immunotherapies have changed cancer care, there are several types of cancer where they have limited or no efficacy. Pheast Therapeutics is addressing that by looking to macrophages, part of the innate immune system. These white blood cells gobble up pathogens, cancer cells, and other foreign substances. Certain tumors, though, can evade their attack by expressing checkpoints that serve as “don’t eat me” signals. Pheast is developing macrophage checkpoint inhibitors to block these

en

32:33

Targeting the Dark Matter of the Genome to Treat...

The Bio Report ·

2024/11/13

About 98 percent of the the human genome consists of non-protein coding regions known as the “dark genome.” Once derided as “junk DNA,” these regions are increasingly understood to play a critical role in the regulation of the genome and offer a novel means of targeting diseases. Haya Therapeutics is exploring long non-coding RNAs as potential therapies to treat a range of diseases. We spoke to Samir Ounzain, co-founder and CEO of Haya, about the dark genome, the potential to use lncRNAs to treat

en

31:33

Using AI to Discover Small Molecule Alternatives to...

The Bio Report ·

2024/11/06

One of the promises of AI is to redefine what’s possible by enabling the discovery of compounds that exist in a much larger chemical space than scientists have previously been able to explore. Deepcure is using AI and physics to discover small molecule therapies that can bind to difficult to target proteins. We spoke to Kfir Schreiber, co-founder and CEO of Deepcure, about the company’s AI technology platform, its focus on autoimmune diseases, and why he believes its technology will allow it to

en

24:40

A BET on a Novel Approach to Treat Autoimmune Conditions

The Bio Report ·

2024/10/30

The BET family of proteins regulates gene expression. Their overexpression has been implicated in both cancer and inflammatory diseases. Vyne Therapeutics is developing oral and topical BET inhibitors that treat inflammatory conditions ranging from rheumatoid arthritis to the skin condition vitiligo. We spoke to Vyne CEO David Domzalski and Vyne Chief Scientific Officer Iain Stuart, about the role BET plays in autoimmune diseases, its platform technology, and its efforts to develop BET inhibitors

en

51:49

Cell Therapies that Can Do a Solid for People with...

The Bio Report ·

2024/10/23

In August, the U.S. Food and Drug Administration approved Adaptimmune’s Tecelra, the first engineered cell therapy to treat a solid tumor. The T cell receptor gene therapy is approved to treat synovial sarcoma, a rare soft tissue cancer that most often affects young adults. We spoke to Adrian Rawcliffe, CEO of Adaptimmune, about the approval, how TCR therapies differ from CAR T therapies, and what other cancers might benefit from such an approach.

en

31:38

Going to Extremes to Discover New Drugs

The Bio Report ·

2024/10/16

Hibernation is not just a matter of deep sleep. Animals that hibernate are able to do so without suffering damage to tissue and muscle. Understanding the biology of hibernation can unlock potential insights into obesity, heart attack and stroke, muscle atrophy, neuroprotection, and longevity. Fauna Bio is studying genomic data from so-called "extreme mammals" and applying its proprietary AI platform to perform comparative genetic analysis to find gene-disease links and leverage millions of years of

en

31:44

Targeting Senescent Cells to Treat Aging-Related...

The Bio Report ·

2024/10/09

Senescent cells, ones that no longer divide but are metabolically active, are associated with aging. They are also implicated in a broad range of aging-related diseases including cancer, diabetes, and neurodegenerative conditions. In the case of cancer, these cells can help protect tumors from a person’s immune system. Immorta Bio is seeking to address aging-related diseases by targeting senescent cells and killing them. We spoke to Thomas Ichim, president and chief scientific officer of Immorta

en

30:35

Bringing Cellular Diversity into Sharper Focus

The Bio Report ·

2024/10/02

From cell to cell within a given tissue, variability exists. Single-cell sequencing technologies from 10X Genomics is helping researchers and drug developers understand cellular diversity in tissue once thought to be made up of homogenous populations. This has the potential to lead to new understandings of diseases, open up new targets for drug developers, and provide for more tailored approaches to the treatment of diseases. We spoke to Michael Schnall-Levin, chief technology officer and founding

en

18:09

Developing Cancer Therapies for When Damage Control...

The Bio Report ·

2024/09/25

The DDR pathway plays a critical role in repairing DNA damage in healthy cells that would otherwise cause mutations or cell death. When this pathway is altered and becomes unable to repair this damage, mutated cells can grow out of control and become cancerous. They can also be more resistant to standard chemotherapies and radiation. Aprea Therapeutics is developing therapies to target mutations in genes in this pathway to treat certain cancers. We spoke to Oren Gilad, president and CEO of Aprea

en

292 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter